AlloVir is a biotechnology company focused on developing allogeneic, off-the-shelf virus-specific T cell (VST) therapies to restore immunity in patients with T cell deficiencies. The company serves patients at risk of severe viral infections, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young. Operating in the biopharmaceutical market, AlloVir's business model revolves around the research, development, and commercialization of VST therapies. The company generates revenue through the sale of its proprietary VST products, which are designed to be immediately available for patients in need. AlloVir's innovative approach involves the adoptive transfer of VSTs generated from healthy donors, aiming to provide a rapid and effective immune response against multiple viruses. The company's recent achievements include FDA clearance for investigational new drug applications, highlighting its commitment to advancing treatment options for high-risk patients.

Keywords: biotechnology, VST therapy, T cell deficiencies, viral infections, immunotherapy, transplant recipients, cancer patients, elderly, FDA clearance, adoptive transfer.